Seaport Therapeutics, Inc. SPTX
Seaport Therapeutics, Inc. (Nasdaq: SPTX) is a CNS/neurology/psychiatry drug developer. Its lead program, GlyphAllo (SPT-300), oral Glyphed prodrug of allopregnanolone, is in Phase 2 for major depressive disorder (MDD) with or without anxious distress. Its next catalyst on record is GlyphAllo: Topline data from Phase 1 driving simulation trial (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: GlyphAllo — Topline data from Phase 1 driving simulation trial (H2 2026). 6 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| GlyphAllo (SPT-300) | MDD with or without anxious distress | small molecule | Phase 2 |
| GlyphAgo (SPT-320), oral Glyphed prodrug of agomelatine | generalized anxiety disorder (GAD) | small molecule | Phase 1 |
| Glyph2BLSD (SPT-348), Glyphed prodrug of 2-bromo-LSD | treatment-resistant depression, PTSD, headache disorders | small molecule | Pre-clinical |
Recent results and decisions
- Jun 8, 2026positive Phase 1 MAD portion: seven-day dosing achieved therapeutic agomelatine exposures at doses projected to avoid liver enzyme elevations; no serious or liver-related AEs.
Repeat dosing of GlyphAgoTM confirms favorable safety, tolerability, and pharmacokinetics across the Phase 1 program, with no serious or liver-related adverse events observed.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.